Lupin sells US copies of 2 of the blockbuster drugs on this tracker, is approved for 3 more, and has 2 filed or in development. Those brands earned $62.4B in 2025. Of the 70 makers we follow, 10 are lined up to copy more of these drugs.
| Drug | Lupin's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| XareltoGeneric · 2.5 mg tablets · Bayer / Johnson & Johnson · US LOE 2025 | 2.5 mg tablets: FDA-approved 3 Mar 2025; launched 7 Mar 2025 | 0 on sale · 18 approvedof 19 other makers listed | ≈$5.3B |
| FarxigaGeneric · AstraZeneca · US LOE 2026 | FDA-approved 6 Apr 2026; launched 10 Apr 2026 | 1 on sale · 13 approvedof 14 other makers listed | $8.4B |
| Drug | Lupin's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| EntrestoGeneric · Novartis · US LOE 2025 | FDA-approved 8 Jan 2025 | 2 on sale · 13 approvedof 15 other makers listed | $7.7B |
| XtandiGeneric · Astellas / Pfizer · US LOE 2027 | Tentatively approved | 0 on sale · 1 approvedof 5 other makers listed | ≈$6.0B |
| EliquisGeneric · Bristol Myers Squibb / Pfizer · US LOE 2028 | Tentatively approved Sep 2026. Apixaban oral suspension, a new liquid form rather than a copy of the tablets | 0 on sale · 2 approvedof 4 other makers listed, plus unnamed filers | $14.4B |
| Drug | Lupin's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| DescovyGeneric · Gilead · US LOE 2031 | FDA-approved 13 Dec 2024, not marketed; settled 2022 | 0 on sale · 2 approvedof 5 other makers listed | $2.8B |
| Drug | Lupin's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| ErleadaGeneric · Johnson & Johnson · US LOE 2033 | Filed with the FDA; in litigation, sued Oct 2026. Settled the first case in Aug 2025; sued again in Oct 2026 over two newer patents (60 mg) | 0 on sale · 1 approvedof 3 other makers listed | $3.6B |
| BiktarvyGeneric · Gilead · US LOE 2036 | Filed with the FDA; settled Oct 2025; US entry allowed from 1 Apr 2036. Subject to standard acceleration provisions | 0 on sale · 0 approvedof 2 other makers listed | $14.3B |
Copies not yet on sale, by the earliest year each could reach the US market: a settlement or court date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.
The brand owner's US sales, as it reports them. They show how fast copies took the market, not Lupin's own sales. See the launch tracker →
Each row is a copy Lupin sells, holds an approval for, has filed, or is developing, for one of the 63 blockbuster drugs this site tracks. It is not Lupin's full portfolio. "Other makers listed" counts the other companies on the same drug's list: how many sell a copy and how many more hold an approval. Brand owners and the FDA don't always name every filer, so a list can be incomplete; the drug page says so where we know.
2025 sales are what each brand earned, the size of the market at stake. They are not Lupin's sales; several makers usually share a market once copies launch.
Every row is sourced on its drug's page: FDA Orange Book and Purple Book approvals, company releases and filings for launches, and court and company records for settlements. Company facts: Screener.